Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• SpaceX (SPCX) gains nearly 6% as traders follow the money
• NVIDIA to invest $100bn for OpenAI data centre in Ohio - FT